ARCHIVES

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Agreement Nears On New Guidelines For Center Grants

November 14, 1980

ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application

September 24, 1999

AACR Using Its Clout To Urge Higher NCI Budget

May 24, 1991

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

May 13, 2005

In Brief: Appropriations Bill Markups Due This Month, With Increases Seen For NCI, NIH, And AIDS

July 3, 1987

Five Contracts Funded Under Unconventional Innovations Program

October 22, 1999